Zacks Investment Research upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a sell rating to a hold rating in a research note released on Wednesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, TheStreet raised shares of Capricor Therapeutics from a d rating to a c- rating in a research report on Tuesday, July 10th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $5.83.

Shares of CAPR traded up $0.01 during trading hours on Wednesday, reaching $0.92. 61,478 shares of the stock traded hands, compared to its average volume of 289,150. Capricor Therapeutics has a 52 week low of $0.88 and a 52 week high of $3.19. The firm has a market capitalization of $32.29 million, a P/E ratio of -2.10 and a beta of -2.65.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Capricor Therapeutics had a net margin of 111.24% and a negative return on equity of 204.82%. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.41 million. As a group, analysts predict that Capricor Therapeutics will post -0.53 earnings per share for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also: What Are Treasury Bonds?

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.